327 related articles for article (PubMed ID: 35879764)
1. Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study.
Ricardo-Silgado ML; Singh S; Cifuentes L; Decker PA; Gonzalez-Izundegui D; Moyer AM; Hurtado MD; Camilleri M; Bielinski SJ; Acosta A
BMC Med; 2022 Jul; 20(1):261. PubMed ID: 35879764
[TBL] [Abstract][Full Text] [Related]
2. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs.
Brouwer JMJL; Nijenhuis M; Soree B; Guchelaar HJ; Swen JJ; van Schaik RHN; Weide JV; Rongen GAPJM; Buunk AM; de Boer-Veger NJ; Houwink EJF; van Westrhenen R; Wilffert B; Deneer VHM; Mulder H
Eur J Hum Genet; 2022 Oct; 30(10):1114-1120. PubMed ID: 34782755
[TBL] [Abstract][Full Text] [Related]
3. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome p450 genotypes.
Berle JØ; Steen VM; Aamo TO; Breilid H; Zahlsen K; Spigset O
J Clin Psychiatry; 2004 Sep; 65(9):1228-34. PubMed ID: 15367050
[TBL] [Abstract][Full Text] [Related]
4. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.
Preskorn SH
Clin Pharmacokinet; 1997; 32 Suppl 1():1-21. PubMed ID: 9068931
[TBL] [Abstract][Full Text] [Related]
5. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.
Jeppesen U; Gram LF; Vistisen K; Loft S; Poulsen HE; Brøsen K
Eur J Clin Pharmacol; 1996; 51(1):73-8. PubMed ID: 8880055
[TBL] [Abstract][Full Text] [Related]
6. CYP2C19-Guided Escitalopram and Sertraline Dosing in Pediatric Patients: A Pharmacokinetic Modeling Study.
Strawn JR; Poweleit EA; Ramsey LB
J Child Adolesc Psychopharmacol; 2019 Jun; 29(5):340-347. PubMed ID: 30817183
[No Abstract] [Full Text] [Related]
7. CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline.
Alfaro CL; Lam YW; Simpson J; Ereshefsky L
J Clin Psychopharmacol; 1999 Apr; 19(2):155-63. PubMed ID: 10211917
[TBL] [Abstract][Full Text] [Related]
8. Pre-clinical drug-drug interactions (DDIs) of gefitinib with/without losartan and selective serotonin reuptake inhibitors (SSRIs): citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine.
Luong TT; Powers CN; Reinhardt BJ; Weina PJ
Curr Res Pharmacol Drug Discov; 2022; 3():100112. PubMed ID: 35756846
[TBL] [Abstract][Full Text] [Related]
9. A cross-sectional study of the relationship between CYP2D6 and CYP2C19 variations and depression symptoms, for women taking SSRIs during pregnancy.
Hippman C; Slomp C; Morris E; Batallones R; Inglis A; Carrion P; Brain U; Higginson M; Wright GEB; Balneaves LG; Ryan D; Nislow C; Ross CJD; Gaedigk A; Oberlander TF; Austin J
Arch Womens Ment Health; 2022 Apr; 25(2):355-365. PubMed ID: 34231053
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.
Baumann P
Clin Pharmacokinet; 1996 Dec; 31(6):444-69. PubMed ID: 8968657
[TBL] [Abstract][Full Text] [Related]
11. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
Ball SE; Ahern D; Scatina J; Kao J
Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics to Predict Adverse Events Associated With Antidepressants.
Rossow KM; Aka IT; Maxwell-Horn AC; Roden DM; Van Driest SL
Pediatrics; 2020 Dec; 146(6):. PubMed ID: 33234666
[TBL] [Abstract][Full Text] [Related]
13. Completed suicides of citalopram users-the role of CYP genotypes and adverse drug interactions.
Rahikainen AL; Vauhkonen P; Pett H; Palo JU; Haukka J; Ojanperä I; Niemi M; Sajantila A
Int J Legal Med; 2019 Mar; 133(2):353-363. PubMed ID: 30173302
[TBL] [Abstract][Full Text] [Related]
14. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.
Hicks JK; Bishop JR; Sangkuhl K; Müller DJ; Ji Y; Leckband SG; Leeder JS; Graham RL; Chiulli DL; LLerena A; Skaar TC; Scott SA; Stingl JC; Klein TE; Caudle KE; Gaedigk A;
Clin Pharmacol Ther; 2015 Aug; 98(2):127-34. PubMed ID: 25974703
[TBL] [Abstract][Full Text] [Related]
15. Effect of Cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors.
Probst-Schendzielorz K; Viviani R; Stingl JC
Expert Opin Drug Metab Toxicol; 2015; 11(8):1219-32. PubMed ID: 26028357
[TBL] [Abstract][Full Text] [Related]
16. Economic consequences of selective serotonin reuptake inhibitor use with drugs also metabolized by the cytochrome P-450 system.
Ozminkowski RJ; Hylan TR; Melfi CA; Meneades LM; Crown WH; Croghan TW; Robinson RL
Clin Ther; 1998; 20(4):780-96. PubMed ID: 9737837
[TBL] [Abstract][Full Text] [Related]
17. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.
Bousman CA; Stevenson JM; Ramsey LB; Sangkuhl K; Hicks JK; Strawn JR; Singh AB; Ruaño G; Mueller DJ; Tsermpini EE; Brown JT; Bell GC; Leeder JS; Gaedigk A; Scott SA; Klein TE; Caudle KE; Bishop JR
Clin Pharmacol Ther; 2023 Jul; 114(1):51-68. PubMed ID: 37032427
[TBL] [Abstract][Full Text] [Related]
18. Some aspects of genetic polymorphism in the biotransformation of antidepressants.
Brøsen K
Therapie; 2004; 59(1):5-12. PubMed ID: 15199661
[TBL] [Abstract][Full Text] [Related]
19. The potential for clinically significant drug-drug interactions involving the CYP 2D6 system: effects with fluoxetine and paroxetine versus sertraline.
Preskorn SH; Shah R; Neff M; Golbeck AL; Choi J
J Psychiatr Pract; 2007 Jan; 13(1):5-12. PubMed ID: 17242587
[TBL] [Abstract][Full Text] [Related]
20. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations.
Alfaro CL; Lam YW; Simpson J; Ereshefsky L
J Clin Pharmacol; 2000 Jan; 40(1):58-66. PubMed ID: 10631623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]